Observations from the CBL0137 hydrochloride solo treatment group and the group receiving a combination of CBL0137 hydrochloride and gemcitabine reveal extensive necrotic areas, a high number of apoptotic bodies, and a significant reduction in tumor cells. Lower doses of CBL0137 hydrochloride, between 50 to 60 mg/kg, enhance the anticancer efficacy of gemcitabine similarly to the maximum tolerated dose (MTD) of 90 mg/kg, underscoring no meaningful difference among the combination treatments. The mechanism of CBL0137 hydrochloride's action involves the inhibition of FACT by depleting the active FACT pool necessary for transcription elongation^[1].

Furthermore, CBL0137 hydrochloride, when orally administered at a safe dosage of 30 mg/kg daily, following a 5 days on/2 days off regimen, effectively curtails tumor growth in xenograft models derived from colon (DLD-1), renal cell carcinoma (Caki-1), melanoma (Mel-7) cell lines, and surgical samples from pancreatic ductal adenocarcinoma patients^[2].

Administering CBL0137 hydrochloride eliminates viable cells at dosages surpassing 2.5 μM. This compound notably diminishes the number of colonies formed, impacting not just MiaPaCa-2 cells but also those resistant to gemcitabine, such as PANC-1 cells. In human pancreatic cancer cell treatments, CBL0137 hydrochloride leads to a concentration-dependent decrease in the protein and mRNA levels of RRM1 and RRM2^[1].